Doxribtimine
Doxribtimine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Kygevvi
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
650 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 79 | 106 | 82 | 27 | 108 | 395 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 42 | 28 | 37 | 10 | 49 | 166 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 3 | 4 | 12 | 24 | 4 | 45 |
| Infections | D007239 | EFO_0000544 | — | 9 | 8 | 11 | 5 | 11 | 44 |
| Hepatitis b | D006509 | — | — | — | 3 | 10 | 14 | 5 | 32 |
| Hiv | D006678 | — | O98.7 | 1 | 5 | 4 | 13 | 1 | 22 |
| Communicable diseases | D003141 | — | — | 6 | 2 | 3 | 1 | 6 | 18 |
| Hepatitis | D006505 | — | K75.9 | — | 1 | 5 | 10 | 1 | 17 |
| Aids-related opportunistic infections | D017088 | — | — | 1 | 2 | 6 | 1 | 6 | 16 |
| Lymphoma | D008223 | — | C85.9 | 2 | 7 | — | 1 | 4 | 14 |
Show 50 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aids-related complex | D000386 | EFO_0007137 | B20 | 28 | 20 | 13 | — | 28 | 89 |
| Colorectal neoplasms | D015179 | — | — | 19 | 28 | 6 | — | 4 | 50 |
| Neoplasms | D009369 | — | C80 | 9 | 3 | 3 | — | 3 | 17 |
| Carcinoma | D002277 | — | C80.0 | 5 | 7 | 2 | — | — | 13 |
| Vaccinia | D014615 | — | — | 7 | 8 | 1 | — | — | 13 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 7 | — | 4 | — | — | 11 |
| Kaposi sarcoma | D012514 | — | C46 | 6 | 1 | 1 | — | 1 | 9 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 3 | 1 | 2 | — | 1 | 7 |
| Infectious pregnancy complications | D011251 | — | — | 4 | — | 3 | — | — | 7 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | — | — | 4 | — | 3 | 7 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | 5 | 9 | — | — | — | 12 |
| Rectal neoplasms | D012004 | — | — | 5 | 5 | — | — | 1 | 10 |
| Colonic neoplasms | D003110 | — | C18 | 3 | 4 | — | — | 2 | 9 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 4 | 5 | — | — | — | 8 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 2 | — | — | 5 | 7 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 5 | — | — | 2 | 7 |
| Melanoma | D008545 | — | — | 5 | 2 | — | — | 1 | 6 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 2 | — | — | 3 | 5 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 3 | — | — | 1 | 4 |
| Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | 1 | 1 | — | — | 2 | 4 |
Show 40 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | 3 | 5 |
| Pancytopenia | D010198 | — | D61.81 | 2 | — | — | — | 3 | 5 |
| Cytopenia | D000095542 | — | — | 2 | — | — | — | 3 | 5 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | 3 | 4 |
| Sarcoma | D012509 | — | — | 3 | — | — | — | 1 | 4 |
| Neutropenia | D009503 | — | D70 | 2 | — | — | — | 1 | 3 |
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | — | 1 | — | — | — | 1 | 2 |
| Tetralogy of fallot | D013771 | EFO_0004894 | Q21.3 | 1 | — | — | — | 1 | 2 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Show 21 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 8 | 8 |
| Cytomegalovirus retinitis | D017726 | EFO_1001302 | — | — | — | — | — | 3 | 3 |
| Retinitis | D012173 | — | H30.9 | — | — | — | — | 3 | 3 |
| Wasting syndrome | D019282 | — | — | — | — | — | — | 1 | 1 |
| Cachexia | D002100 | — | R64 | — | — | — | — | 1 | 1 |
| Triple negative breast neoplasms | D064726 | — | — | — | — | — | — | 1 | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
| Digeorge syndrome | D004062 | — | D82.1 | — | — | — | — | 1 | 1 |
| Aneuploidy | D000782 | — | — | — | — | — | — | 1 | 1 |
| Klinefelter syndrome | D007713 | EFO_1001006 | Q98.0 | — | — | — | — | 1 | 1 |
Show 37 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Doxribtimine |
| INN | doxribtimine |
| Description | 1-(2-Deoxypentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione is a pyrimidine 2'-deoxyribonucleoside. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O |
Identifiers
| PDB | — |
| CAS-ID | 50-89-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL52609 |
| ChEBI ID | 17748 |
| PubChem CID | 1134 |
| DrugBank | DB04485 |
| UNII ID | VC2W18DGKR (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
105 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use